Strides’ Stelis Wins FDA Approval For Bengalaru Injectables Facility
Paves the Way For The Firm’s Continued Push Into US Market
Stelis BioPharma’s flagship Indian manufacturing facility has been cleared under an FDA Establishment Inspection Report.
You may also be interested in...
Hyloris Pharmaceuticals’ new idiopathic rhinitis treatment sets it on track to achieve its target of around 30 portfolio assets by the end of 2024.
Zentiva gains semi-exclusive commercialization rights to Biocon’s liraglutide drug-device combination in 30 countries, following a string of similar deals for the company since its 2018 acquisition.
Teva’s new partnerships will make patient data from its digital inhalers more accessible to healthcare providers, potentially placing Teva’s asthma platform at the forefront of emerging treatment paradigms.